Lindbrook Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Lindbrook Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-544	Closed	-$1.78K	–	2759
2024 Q1	$1.78K	Hold	544	–	–	﹤0.01%	2283
2023 Q4	$1.91K	Sell	544 -234	-30%	-$722	﹤0.01%	2278
2023 Q3	$5.2K	Hold	778	–	–	﹤0.01%	1744
2023 Q2	$6.53K	Buy	778 +417	+116%	+$4.11K	﹤0.01%	1681
2023 Q1	$3.58K	Sell	361 -151	-29%	-$1.07K	﹤0.01%	1998
2022 Q4	$3.56K	Sell	512 -249	-33%	-$1.42K	﹤0.01%	1977
2022 Q3	$4K	Hold	761	–	–	﹤0.01%	1722
2022 Q2	$3K	Hold	761	–	–	﹤0.01%	1732
2022 Q1	$3K	Sell	761 -1,780	-70%	-$7.09K	﹤0.01%	1774
2021 Q4	$10K	Buy	+2,541	New	+$19.4K	﹤0.01%	1250
2019 Q4	–	Sell	-3,000	Closed	-$16K	–	1495
2019 Q3	$16K	Hold	3,000	–	–	0.01%	774
2019 Q2	$18K	Buy	+3,000	New	+$22.6K	0.01%	729

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lindbrook Capital's ALDX Position: Q2 2024 in Review

Lindbrook Capital sold out of Aldeyra Therapeutics (ALDX) in Q2 2024, closing a stake of 544 shares — an estimated $1.78K sold.

Lindbrook Capital first reported a position in ALDX in Q2 2019 and held it in 12 quarters. The position peaked at $18K in Q2 2019. 103 funds tracked by Wall St. Rank hold ALDX as of Q2 2024.

Lindbrook Capital reported no remaining Aldeyra Therapeutics position as of Q2 2024 after selling out during the quarter.
Lindbrook Capital sold 544 Aldeyra Therapeutics shares in Q2 2024, an estimated $1.78K.
Lindbrook Capital first reported a position in Aldeyra Therapeutics in Q2 2019 and held it in 12 quarters.
Lindbrook Capital's Aldeyra Therapeutics position peaked at $18K in Q2 2019.
103 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2024.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.